### KDM2A Gene Overview

The KDM2A gene encodes a member of the F-box protein family, specifically classified under the Fbls class, which contains an F-box motif and several leucine-rich repeats. KDM2A is recognized for its role in histone demethylation, primarily targeting lysine-36 (H3K36) of histone H3, which plays a crucial role in epigenetic regulation and gene expression. Its functions extend to maintaining genomic stability, particularly during mitosis, by repressing specific transcriptional activities and facilitating the degradation of certain phosphorylated proteins through ubiquitination.

### 1. Associated Genes
KDM2A is associated with several other genes and may interact with various signaling pathways. Some notable genes that show interactions or associations include:
- **JARID1B**: Similar to KDM2A, it is involved in histone demethylation and epigenetic regulation.
- **SETDB1**: An enzyme associated with histone methylation which may provide a balance to the actions of KDM2A.
- **CBX3**: This gene encodes a chromobox protein that may interact with KDM2A in pathways involving chromatin remodeling.

### 2. Age-Related Associations
KDM2A has been implicated in aging and age-related diseases, primarily through its role in maintaining genomic stability and epigenetic regulation. Some correlations include:
- **Cancer**: Aberrant expression of KDM2A has been linked to tumorigenesis and the progression of various cancers, suggesting that its altered function may contribute to age-related increases in cancer incidence.
- **Neurodegenerative Diseases**: Dysregulation of histone demethylation by KDM2A might affect cellular mechanisms contributing to diseases such as Alzheimer’s, as age-related changes in epigenetic modifications are observed in the brains of affected individuals.
- **Cellular Senescence**: The role of KDM2A in maintaining heterochromatic states may influence the process of cellular senescence, which is a significant aspect of organismal aging.

### 3. Known Drug Interactions
While KDM2A itself may not have direct drug interactions, its functions are influenced by broader biological pathways often targeted by certain drugs:
- **Histone Deacetylase Inhibitors**: Such drugs can indirectly affect KDM2A-mediated pathways by altering the surrounding epigenetic landscape.
- **Proteasome Inhibitors**: Drugs that inhibit proteasomal degradation pathways may impact the ubiquitination processes that are influenced by KDM2A.
- **Anticancer Drugs**: Given its role in tumor regulation, drugs targeting the epigenetic mechanisms (e.g., DNA methyltransferase inhibitors) might also modulate KDM2A activity.

### 4. Pathways and Biological Processes
KDM2A is involved in multiple biological processes and pathways, including:
- **Chromatin Remodeling**: KDM2A plays a vital role in the epigenetic landscape by modifying histones, thereby actively participating in the regulation of chromatin structure and gene accessibility.
- **CpG Methylation and Demethylation**: It functions in the demethylation of histone residues, influencing gene transcription dynamics.
- **Ubiquitination and Proteolysis**: KDM2A contributes to the ubiquitination of proteins, marking them for degradation, a crucial process in maintaining cellular homeostasis and responding to stress.
- **Centromeric Integrity Maintenance**: Essential for the proper functioning of centromeres during mitotic processes, affecting chromosomal stability.
- **Regulation of Gene Expression**: Modulation of circadian rhythms, influencing transcriptional activators such as CLOCK, BMAL1, and RORA.

### Conclusion
KDM2A is a multifaceted gene that plays a significant role in epigenetic regulation, genomic stability, and potentially in age-related diseases. Its interactions with various genes and pathways reveal its importance in both developmental biology and pathophysiology, making it a notable target for further research, particularly within the context of cancer and neurodegeneration.